EyePoint Pharmaceuticals reports $2.4M revenue for 3-months end: 3 details

EyePoint Pharmaceuticals released its reports for the three and six-month fiscal periods which ended December 31, 2018.

The key details to know:

1. For the three month period that ended in December 2018, revenue totaled $2.4 million, compared to $933,000 for the same period year-over-year.

2. For the six month transition period that ended in December 2018, revenues totaled $2.9 million, compared to the same period year-over-year.

3. Cash and equivalents in December 2018 totaled $45.3 million compared to $38.8 million in June 2018.

4. In February, the company secured $60 million in debt facility with CR Group L.P., and plan to use the funding to retire a previous secured term loan provide working capital to support commercial launches of two products.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers